Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

iRASP – Platform for the discovery of new tumor-specific therapeutic antibodies

Antibody discovery platformBV2021Cancer immunotherapyIn vivo screeningTumor antigens


Immunotherapies have dramatically changed the natural history of several cancer types. However, due to the paucity of viable tumor antigens discovered by the standard target-first approach, only few antibody-based drugs have entered into clinical use. Our iRASP platform allows to unbiasedly identify tumor-specific therapeutic antibodies, without prior knowledge of their target antigens.

Technical features

iRASP (in vivo Recombinant Antibody-Screening Platform) is a unique platform that relies on antibody phage display library, in vivo screenings and next generation sequencing (NGS) to discover new therapeutic antibodies for cancer patients. It is a fast and cost-effectiveness platform that allows to in vivo isolate tumor-binding phage antibodies directly from tumor-bearing mice, and then shortlist the selected in vivo tumor-binders on the basis of their tumor specificity, thanks to a reliable and robust prioritization process. iRASP has been successfully validated in refractory T-cell acute lymphoblastic leukaemia (T-ALL), but it can be tailored and applied to virtually any tumor type for the development of new and more effective immunotherapies for cancer patients.

Possible Applications

  • Cancer immunotherapies (i.e. naked therapeutic antibody, immuno-cytokine, bispecific antibody, CAR-T therapy).


  • In vivo selection of antibodies against patient-derived xenografts (PDXs);
  • In vitro antibody engineering for optimization of the antibody format;
  • Discovery of new tumor antigens endowed with validated antigenicity;
  • Great adaptation to different phage display libraries and diverse tumor types.